Zura Bio is a clinical-stage immunology company developing dual-pathway antibody therapies for serious autoimmune and inflammatory diseases. Its lead candidate, tibulizumab (ZB-106), is in Phase 2 studies for systemic sclerosis and hidradenitis suppurativa. Additional assets, including crebankitug and torudokimab, target key immune pathways with the aim of improving efficacy, safety and dosing convenience where existing options leave unmet need.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -16 | — |
| Q3 2025 | 0 | — | -20 | — |
| Q4 2025 | 0 | — | -45.9 | — |
| Q1 2026 | 0 | — | -24.2 | — |
| Q2 2026 | 0 | — | -26.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: GigCapital8 Corp. (GIW), Funko, Inc. (FNKO), FRP Holdings, Inc. (FRPH), Lotus Technology Inc. (LOT), Siddhi Acquisition Corp. (SDHI), ONE Nuclear Energy Inc. (ONEN)